Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria (Q28256613)

2

0 references

Christopher F Mojcik

3

0 references

Robert A Brodsky

4

0 references

Leonard Bell

Complement-specific antibodies: designing novel anti-inflammatories

5

0 references

language of work or name

English

0 references

publication date

November 2007

0 references

published in

Nature Biotechnology

0 references

volume

25

0 references

page(s)

1256-64

0 references

issue

11

0 references

cites work

1 reference

7 January 2021

Complement. Second of two parts

1 reference

7 January 2021

The structure of complement C3b provides insights into complement activation and regulation.

1 reference

7 January 2021

Structures of complement component C3 provide insights into the function and evolution of immunity

1 reference

7 January 2021

Structure of C3b reveals conformational changes that underlie complement activity

1 reference

7 January 2021

Structure of C3b in complex with CRIg gives insights into regulation of complement activation

1 reference

7 January 2021

Indications for the immunological evaluation of patients with meningitis

1 reference

7 January 2021

Generation of C5a in the absence of C3: a new complement activation pathway

1 reference

7 January 2021

Molecular organization and function of the complement system

1 reference

7 January 2021

The N-formyl peptide receptors and the anaphylatoxin C5a receptors: an overview

1 reference

7 January 2021

C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a

1 reference

7 January 2021

Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria

1 reference

7 January 2021

Paroxysmal nocturnal hemoglobinuria due to hereditary nucleotide deletion in the HRF20 (CD59) gene

1 reference

7 January 2021

Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine

1 reference

7 January 2021

Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv.

1 reference

7 January 2021

Reshaping human antibodies for therapy

1 reference

7 January 2021

Expressed human immunoglobulin kappa genes and their hypermutation

1 reference

7 January 2021

Humanized porcine VCAM-specific monoclonal antibodies with chimeric IgG2/G4 constant regions block human leukocyte binding to porcine endothelial cells

1 reference

7 January 2021

The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region

1 reference

7 January 2021

Human antibody effector function

1 reference

7 January 2021

Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation

1 reference

7 January 2021

Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria

1 reference

7 January 2021

Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease

1 reference

7 January 2021

Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.

1 reference

7 January 2021

Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus

1 reference

7 January 2021

Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial.

1 reference

7 January 2021

Pexelizumab and the APEX AMI trial

1 reference

7 January 2021

Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes

1 reference

7 January 2021

Diagnosis and management of paroxysmal nocturnal hemoglobinuria

1 reference

7 January 2021

Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria

1 reference

7 January 2021

PIG-A mutations in normal hematopoiesis

1 reference

7 January 2021

Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals

1 reference

7 January 2021

The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment.

1 reference

7 January 2021

Paroxysmal nocturnal hemoglobinuria type III. Lack of an erythrocyte membrane protein restricting the lysis by C5b-9.

1 reference

7 January 2021

Erythrocytes of patients with paroxysmal nocturnal haemoglobinuria acquire resistance to complement attack by purified 20-kD homologous restriction factor

1 reference

7 January 2021

Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria

1 reference

7 January 2021

Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes. Studies on C9 binding and incorporation into high molecular weight complexes

1 reference

7 January 2021

1 reference

7 January 2021

Fatigue in cancer patients compared with fatigue in the general United States population.

1 reference

7 January 2021

Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes.

1 reference

7 January 2021

The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease

1 reference

7 January 2021

Activated platelets in paroxysmal nocturnal haemoglobinuria

1 reference

7 January 2021

Cerebral ischemic infarction in paroxysmal nocturnal hemoglobinuria report of 2 cases and updated review of 7 previously published patients

1 reference

7 January 2021

Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH).

1 reference

7 January 2021

Enhancement of platelet deposition by cross-linked hemoglobin in a rat carotid endarterectomy model

1 reference

7 January 2021

Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium

1 reference

7 January 2021

The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide

1 reference

7 January 2021

Inhibition of clotting factor XIII activity by nitric oxide.

1 reference

7 January 2021

Reduced nitric oxide production by L-arginine deficiency in lysinuric protein intolerance exacerbates intravascular coagulation

1 reference

7 January 2021

Natural history of paroxysmal nocturnal hemoglobinuria

1 reference

7 January 2021

Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology

1 reference

7 January 2021

Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays

1 reference

7 January 2021

High incidence of thrombosis in African-American and Latin-American patients with Paroxysmal Nocturnal Haemoglobinuria

1 reference

7 January 2021

Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan.

1 reference

7 January 2021

Efficient retrovirus-mediated PIG-A gene transfer and stable restoration of GPI-anchored protein expression in cells with the PNH phenotype

1 reference

7 January 2021

Paroxysmal nocturnal haemoglobinuria with coexisting deficiency of the ninth component of complement: lack of massive haemolytic attack

1 reference

7 January 2021

Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria

1 reference

7 January 2021

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria

1 reference

7 January 2021

Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.

1 reference

7 January 2021

Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine

1 reference

7 January 2021

The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice

1 reference

7 January 2021

In vitro demyelination by serum antibody from patients with guillain-barré syndrome requires terminal complement complexes

1 reference

7 January 2021

Basic and clinical aspects of autoimmune disorders in peripheral nerves

1 reference

7 January 2021

Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome

1 reference

7 January 2021

A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways.

1 reference

7 January 2021

Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange

1 reference

7 January 2021

Role of C5 in the development of airway inflammation, airway hyperresponsiveness, and ongoing airway response

1 reference

7 January 2021

Drusen complement components C3a and C5a promote choroidal neovascularization

1 reference

7 January 2021